Stockscreener 앱 받기
14.30
5.77%
0.78
전일 마감가:
$13.52
열려 있는:
$13.555
하루 거래량:
1.71M
Relative Volume:
1.11
시가총액:
$1.57B
수익:
$-249.00K
순이익/손실:
$-187.60M
주가수익비율:
-5.72
EPS:
-2.5
순현금흐름:
$-201.88M
1주 성능:
+17.12%
1개월 성능:
+16.17%
6개월 성능:
+69.63%
1년 성능:
+308.57%
1일 변동 폭
$13.45
$14.65
1주일 범위
$12.08
$14.65
52주 변동 폭
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.30 | 1.48B | -249.00K | -187.60M | -201.88M | -2.50 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Amylyx Pharmaceuticals Strengthens Clinical-Stage Development - Kalkine Media
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Finviz
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuation2025 Technical Overview & Short-Term Trading Alerts - Улправда
How Amylyx Pharmaceuticals’ (AMLX) Move Into GLP-1 Rare Diseases Has Changed Its Investment Story - Sahm
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside - TipRanks
Amylyx selects AMX-0318 as development candidate - BioWorld MedTech
Amylyx selects AMX0318 as development candidate for PBH - Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock recession proofJuly 2025 Reactions & Stepwise Entry/Exit Trade Alerts - Улправда
Why Amylyx Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Community Consensus Stock Picks - Улправда
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks
James Frates Sells 3,326 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program By Investing.com - Investing.com Nigeria
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com Nigeria
US company unveils candidate for Gubra partnership - medwatch.com
Amylyx Advances AMX0318 as New Rare-Disease Candidate - TipRanks
Amylyx Pharmaceuticals, Inc. Announces Development of AMX0318 - TradingView — Track All Markets
Long-acting GLP-1 antagonist named for rare post-bariatric hypoglycemia - Stock Titan
Will Amylyx Pharmaceuticals Inc. stock deliver long term returns2026 world cup usa national team semifinals top scorers set piece tactics tactical prediction breakdown - Улправда
Amylyx Pharmaceuticals Q3 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals, Inc.Common Stock (Nasdaq:AMLX) Stock Quote - FinancialContent
Amylyx Pharmaceuticals pushes for novel therapy development - Traders Union
Relative Strength Alert For Amylyx Pharmaceuticals - Nasdaq
Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress - Sahm
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 12.96% to 20.74 - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 7.2%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Guidance Update: What margin trends mean for Amylyx Pharmaceuticals Inc stockPortfolio Return Summary & Daily Oversold Bounce Ideas - moha.gov.vn
Hedge Fund and Insider Trading News: Ken Griffin, Ray Dalio, Warren Buffett, Toms Capital, Ken Fisher, Pershing Square, Amylyx Pharmaceuticals Inc (AMLX), NVIDIA Corp (NVDA), and More - Insider Monkey
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase - Quiver Quantitative
Amylyx announces proposed public offering of common stock - MSN
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying - Sahm
Amylyx Pharma director Firestone buys $100k in AMLX stock By Investing.com - Investing.com UK
Amylyx Pharma director Firestone buys $100k in AMLX stock - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Acquires $100,845.00 in Stock - MarketBeat
Amylyx Pharmaceuticals Director Karen Firestone Acquires 8,100 Shares - TradingView — Track All Markets
How Amylyx Pharmaceuticals Inc. stock trades before earningsLayoff News & Verified Momentum Watchlists - Улправда
Will Amylyx Pharmaceuticals Inc. stock recover faster than peers2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Will Amylyx Pharmaceuticals Inc. stock return to pre crisis levelsBull Run & Expert Approved Momentum Trade Ideas - Улправда
Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotation2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
What margin trends mean for Amylyx Pharmaceuticals Inc. stockMarket Activity Summary & High Conviction Buy Zone Picks - DonanımHaber
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.45%
자본화:
|
볼륨(24시간):